Latest Ratios: P/E Ratio 70.7x · EV/EBITDA 60.9x · ROE 13.8%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $12.6B | $12.2B | $9.3B | $9.9B | $8.4B | $10.9B | $6.3B | $6.0B | $4.4B | $3.3B | $2.1B |
| Enterprise Value | $12.6B | $12.2B | $9.2B | $9.9B | $8.6B | $11.0B | $6.3B | $6.0B | $4.3B | $3.3B | $2.1B |
| P/E Ratio → | 70.67 | 68.79 | 659.67 | 108.42 | — | 2052.29 | — | 122.59 | 678.89 | 723.85 | 145.00 |
| P/S Ratio | 8.95 | 8.70 | 7.81 | 9.32 | 9.94 | 14.56 | 11.17 | 10.88 | 9.91 | 9.96 | 8.11 |
| P/B Ratio | 8.79 | 8.56 | 8.10 | 8.37 | 8.43 | 11.41 | 9.81 | 12.27 | 10.44 | 8.30 | 8.01 |
| P/FCF | 71.82 | 69.83 | 63.31 | 120.12 | — | — | — | 1311.34 | 229.62 | — | — |
| P/OCF | 52.64 | 51.19 | 55.35 | 101.35 | — | 1145.45 | — | 223.53 | 153.08 | 261.88 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.73 | 7.72 | 9.38 | 10.13 | 14.71 | 11.18 | 10.90 | 9.76 | 9.81 | 8.06 |
| EV / EBITDA | 60.94 | 59.25 | 279.69 | 98.52 | 282.35 | 1234.78 | — | 107.30 | 816.77 | 661.72 | 2241.46 |
| EV / EBIT | 66.56 | 59.71 | 413.89 | 122.02 | 1521.75 | — | — | 125.60 | 144.81 | 2809.35 | — |
| EV / FCF | — | 70.02 | 62.62 | 120.94 | — | — | — | 1313.43 | 226.08 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.1% | 67.1% | 63.2% | 64.5% | 63.2% | 63.6% | 60.3% | 68.0% | 65.7% | 65.1% | 64.9% |
| Operating Margin | 13.5% | 13.5% | 0.8% | 6.9% | 0.7% | -1.0% | -6.9% | 8.7% | -0.2% | 0.3% | -0.5% |
| Net Profit Margin | 12.7% | 12.7% | 1.2% | 8.6% | -0.2% | 0.7% | -2.8% | 8.9% | 1.5% | 1.4% | 5.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 13.8% | 13.8% | 1.2% | 8.4% | -0.2% | 0.7% | -2.8% | 10.7% | 1.6% | 1.4% | 5.9% |
| ROA | 10.6% | 10.6% | 0.9% | 6.2% | -0.2% | 0.5% | -2.1% | 8.2% | 1.3% | 1.2% | 5.2% |
| ROIC | 11.3% | 11.3% | 0.6% | 4.6% | 0.4% | -0.7% | -5.1% | 8.4% | -0.2% | 0.3% | -0.4% |
| ROCE | 12.5% | 12.5% | 0.7% | 5.6% | 0.5% | -0.8% | -6.0% | 9.3% | -0.2% | 0.3% | -0.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.19 | 0.20 | 0.24 | 0.18 | 0.12 | 0.17 | — | — | — |
| Debt / EBITDA | 1.06 | 1.06 | 6.77 | 2.32 | 7.75 | 19.48 | — | 1.48 | — | — | — |
| Net Debt / Equity | — | 0.02 | -0.09 | 0.06 | 0.17 | 0.12 | 0.01 | 0.02 | -0.16 | -0.13 | -0.05 |
| Net Debt / EBITDA | 0.16 | 0.16 | -3.06 | 0.66 | 5.46 | 12.82 | — | 0.17 | -12.76 | -10.24 | -13.98 |
| Debt / FCF | — | 0.19 | -0.69 | 0.81 | — | — | — | 2.10 | -3.53 | — | — |
| Interest Coverage | 156.46 | 156.46 | 15.72 | 46.80 | 3.23 | -4.43 | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.64 | 6.64 | 6.01 | 6.06 | 5.21 | 5.53 | 5.83 | 5.09 | 6.22 | 7.41 | 7.37 |
| Quick Ratio | 4.29 | 4.29 | 3.44 | 3.49 | 2.91 | 3.39 | 3.76 | 3.41 | 4.47 | 5.57 | 5.33 |
| Cash Ratio | 1.02 | 1.02 | 2.15 | 1.91 | 1.30 | 2.07 | 2.50 | 2.08 | 3.04 | 4.16 | 3.60 |
| Asset Turnover | — | 0.77 | 0.78 | 0.68 | 0.62 | 0.60 | 0.68 | 0.82 | 0.86 | 0.70 | 0.85 |
| Inventory Turnover | 1.07 | 1.07 | 1.08 | 0.97 | 0.93 | 1.03 | 1.01 | 1.15 | 1.32 | 1.23 | 1.27 |
| Days Sales Outstanding | — | 49.41 | 51.23 | 69.57 | 87.63 | 65.39 | 74.64 | 70.61 | 67.18 | 63.44 | 60.07 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.4% | 1.5% | 0.2% | 0.9% | — | 0.0% | — | 0.8% | 0.1% | 0.1% | 0.7% |
| FCF Yield | 1.4% | 1.4% | 1.6% | 0.8% | — | — | — | 0.1% | 0.4% | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | 0.1% |
| Shares Outstanding | — | $39M | $39M | $39M | $38M | $38M | $36M | $36M | $36M | $35M | $33M |
Includes 30+ ratios · 13 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PEN stock.
Penumbra, Inc.'s current P/E ratio is 70.7x. The historical average is 111.2x. This places it at the 25th percentile of its historical range.
Penumbra, Inc.'s current EV/EBITDA is 60.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 78.9x.
Penumbra, Inc.'s return on equity (ROE) is 13.8%. The historical average is 3.9%.
Based on historical data, Penumbra, Inc. is trading at a P/E of 70.7x. This is at the 25th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Penumbra, Inc. has 67.1% gross margin and 13.5% operating margin. Operating margin between 10-20% is typical for established companies.
Penumbra, Inc.'s Debt/EBITDA ratio is 1.1x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
EPS miss and competition
Metrics are mathematically derived from official filings.
Margin Squeeze Amidst Reinvestment
Operating margin contracted to 10.5% in 2026Q2 from 15.4% in 2025Q4, as per recent financial statements, while gross margin held at 67.9%, indicating that rising SG&A is eroding profitability despite stable product pricing.
The 570 basis point decline in operating margin over two quarters, as reported in the latest quarterly data, suggests that the company is reinvesting heavily in sales force expansion and R&D to defend its competitive position, particularly in the vascular segment. Net margin fell to 8.9% in 2026Q2 from 12.3% in 2025Q4, reflecting not only operating pressure but also a higher tax rate or non-recurring items. Investors should monitor whether this margin compression is temporary as Thunderbolt and Real System scale, or if it signals a structural shift toward lower incremental profitability.
Return on Capital Decelerating
ROIC declined to 2.1% in 2026Q2 from 3.3% in 2025Q4, based on reported figures, while ROE fell to 2.3% from 3.4%, indicating that the company's capital base is expanding faster than operating income.
The sequential decline in ROIC, despite stable gross margins, suggests that the company is deploying capital into inventory and PP&E ahead of revenue growth, as evidenced by DIO rising to 320 days and PP&E up 18% year-over-year. This may indicate that the company is building capacity for future growth, but it also implies that returns on invested capital will remain subdued until revenue catches up. The negative ROIC in 2024Q2 (-5.2%) highlights the volatility in this metric, which is sensitive to one-time charges and inventory write-downs.
Working Capital Drag Intensifies
Cash conversion cycle lengthened to 332 days in 2026Q2 from 295 days in 2024Q2, as per recent financial statements, driven by DIO rising to 320 days, indicating that inventory is tying up increasing amounts of cash.
The 25-day increase in CCC over two years, as reported in the latest quarterly data, suggests that the company is building inventory in anticipation of new product launches or experiencing slower turnover due to competitive pressures. DSO improved to 44 days from 64 days in 2024Q1, indicating better receivables collection, but this was more than offset by the inventory build. The high DIO of 320 days is unusual for a medical device company and may reflect consignment arrangements or the need to stock multiple product generations, which warrants close monitoring for potential obsolescence.
Minimal Debt, Ample Flexibility
Debt-to-equity stands at 0.14 with interest coverage of 149.5x in 2026Q2, as reported in financial statements, indicating that the company has negligible leverage and can comfortably service its debt obligations.
The company's conservative capital structure, with total debt of $212.7M against a $2.0B asset base, provides significant financial flexibility to fund organic growth initiatives without refinancing risk. Interest coverage of 149.5x, based on reported figures, suggests that even if operating income were to decline substantially, debt service would remain manageable. However, the D/EBITDA ratio of 4.56 appears elevated relative to the low debt level, which may indicate that EBITDA is depressed due to margin compression, but this is not a concern given the absolute low debt.
Liquidity Buffer Remains Strong
Current ratio of 5.75 and quick ratio of 3.86 in 2026Q2, as per recent balance sheet data, indicate that the company has ample short-term assets to cover liabilities, even with a significant cash drawdown from $421.8M to $205.3M year-over-year.
Despite the reduction in cash, the company's liquidity position remains robust, with current assets exceeding current liabilities by a wide margin. The quick ratio of 3.86, which excludes inventory, suggests that even if inventory became illiquid, the company could meet its short-term obligations. This strong liquidity provides a cushion against operational disruptions or competitive pressures, but investors should note that the cash burn may continue if the company invests heavily in new product launches and international expansion.
Misapplied P/E on Cyclical Earnings
The trailing P/E of 71.5 and forward P/E of 66.0, based on reported figures, are commonly used to gauge value, but they obscure the impact of stock-based compensation and the lumpy nature of earnings, which have swung from negative to positive over the past year.
The P/E ratio is misleading for Penumbra because earnings are volatile and heavily influenced by non-cash charges like SBC, which averaged $13.4M per quarter, and one-time items such as the 2024Q2 inventory write-down. A more appropriate metric is EV/EBITDA, which at 61.65 still appears rich but better captures the company's cash-generating ability before non-cash charges. Alternatively, investors should focus on price-to-sales (9.06) or EV/sales, as revenue growth is the primary driver of value in this high-growth med-tech story, and earnings may not normalize for several quarters.